A New Class of T-Cell Bispecific Antibodies for the Treatment of Multiple Myeloma, Binding to B Cell Maturation Antigen and CD3 and Showing Potent, Specific Antitumor Activity in Myeloma Cells and Long Duration of Action in Cynomolgus Monkeys

被引：4

作者：

Minh Diem Vu ^{[1
]}

Moser, Samuel ^{[2
]}

Delon, Camille ^{[2
]}

Latzko, Melanie ^{[2
]}

Gianotti, Reto ^{[2
]}

Lueoend, Remo ^{[2
]}

Friang, Chloe ^{[2
]}

Murr, Ramona ^{[2
]}

Duerner, Lydia Jasmin ^{[2
]}

Weinzierl, Tina ^{[2
]}

Fauti, Tanja ^{[2
]}

Bacac, Marina ^{[2
]}

Ast, Oliver ^{[2
]}

Freimoser-Grundschober, Anne ^{[2
]}

Diaz, Tea Rodriguez ^{[2
]}

Zielonka, Joerg ^{[2
]}

van Puijenbroek, Erwin ^{[2
]}

Hosse, Ralf ^{[2
]}

Bruenker, Peter ^{[2
]}

Moessner, Ekkehard ^{[2
]}

Klein, Christian ^{[2
]}

Umana, Pablo ^{[2
]}

Strein, Klaus ^{[1
]}

机构：

[1] EngMab AG, Wilen, Switzerland

[2] Roche Innovat Ctr Zurich, Schlieren, Switzerland

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

10.1182/blood.V126.23.2998.2998

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[41] Results from a first-in-human phase I study of F182112, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma.
Sun, Mingyuan
Qiu, Lugui
Wei, Yongqiang
Jin, Jie
Li, Xin
Liu, Xue
Yin, Shaohong
Qi, Junyuan
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[42] Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Lesokhin, Alexander M.
Levy, Moshe Y.
Dalovisio, Andrew P.
Bahlis, Nizar J.
Solh, Melhem
Sebag, Michael
Jakubowiak, Andrzej
Jethava, Yogesh S.
Costello, Caitlin L.
Chu, Michael P.
Savona, Michael R.
Gasparetto, Cristina
Trudel, Suzanne
Chou, Jeffrey
Udata, Chandrasekhar
Basu, Cynthia
Krupka, Heike I.
Raje, Noopur S.
BLOOD, 2020, 136
[43] Target expression, preclinical activity and mechanism of action of EM801: a novel first-in-class IgG-based BCMA T-cell bispecific antibody for the treatment of multiple myeloma
Seckinger, A.
Delgado, J. A.
Moreno, L.
Neuber, B.
Grab, A. L.
Lipp, S.
Merino, J.
Vu, M. D.
Strein, K.
Prosper, F.
Hundemer, M.
San Miguel, J.
Hose, D.
Paiva, B.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 207 - 208
[44] A Phase I, Open-Label Study to Evaluate the Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity of PF-06863135, a B-Cell Maturation Antigen/CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Advanced Multiple Myeloma
Lesokhin, Alexander M.
Raje, Noopur
Gasparetto, Cristina J.
Walker, Justine
Krupka, Heike I.
Joh, Tenshang
Taylor, Carrie T.
Jakubowiak, Andrzej
BLOOD, 2018, 132
[45] Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study.
Mohty, Mohamad
Tomasson, Michael H.
Arnulf, Bertrand
Bahlis, Nizar J.
Prince, H. Miles
Niesvizky, Ruben
Rodriguez-Otero, Paula
Martinez-Lopez, Joaquin
Koehne, Guenther
Jethava, Yogesh
Gabayan, A. Eli
Stevens, Don A.
Nooka, Ajay K.
Raje, Noopur S.
Iida, Shinsuke
Leip, Eric
Conte, Umberto
Czibere, Akos Gabor
Viqueira, Andrea
Lesokhin, Alexander M.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[46] Early Pharmacodynamic Changes in T-Cell Activation, Proliferation, and Cytokine Production Confirm the Mode of Action of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
Nakamura, Rin
Lear, Sean
Wilson, Deanna
Koeppen, Hartmut
Vaze, Anjali
Trudel, Suzanne
Spencer, Andrew
Harrison, Simon J.
Cohen, Adam D.
Fine, Bernard M.
Li, Mengsong
Cooper, James
Sumiyoshi, Teiko
BLOOD, 2020, 136
[47] Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM).
Lesokhin, Alexander M.
Arnulf, Bertrand
Niesvizky, Ruben
Mohty, Mohamad
Bahlis, Nizar J.
Tomasson, Michael H.
Rodriguez-Otero, Paula
Quach, Hang
Raje, Noopur S.
Iida, Shinsuke
Raab, Marc-Steffen
Czibere, Akos
Sullivan, Sharon
Leip, Eric
Viqueira, Andrea
Leleu, Xavier
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[48] Expansion of circulating T cells expressing low levels of the B cell-specific antigen CD20 (CD3+CD20dim) in patients with multiple myeloma.
Katopodis, O
Sfikakis, PP
Viglis, V
Liossis, SNC
Pouli, A
Dimopoulos, MA
BLOOD, 2000, 96 (11) : 277B - 277B
[49] Immunotherapy with Long-Lived Anti-CD20 x Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human B Cell Lines and of Circulating and Lymphoid B Cells in Monkeys: A Potential Therapy for B Cell Lymphomas and Leukemias
Chu, Seung Y.
Lee, Sung-Hyung
Rashid, Rumana
Chen, Hsing
Chan, Emily W.
Phung, Sheryl
Pong, Erik
Endo, Nancy A.
Miranda, Yvonne
Bonzon, Christine
Leung, Irene W. L.
Muchhal, Umesh S.
Moore, Gregory L.
Bernett, Matthew J.
Szymkowski, David E.
Desjarlais, John R.
BLOOD, 2014, 124 (21)
[50] Efficacy and safety of teclistamab (tec), a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM) after exposure to other BCMA-targeted agents.
Touzeau, Cyrille
Krishnan, Amrita Y.
Moreau, Philippe
Perrot, Aurore
Usmani, Saad Zafar
Manier, Salomon
Cavo, Michele
Martinez-Chamorro, Carmen
Nooka, Ajay K.
Martin, Thomas G.
Karlin, Lionel
Leleu, Xavier
Bahlis, Nizar J.
Besemer, Britta
Pei, Lixia
Verona, Raluca
Girgis, Suzette
Uhlar, Clarissa
Kobos, Rachel
Garfall, Alfred L.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →